Home > Boards > US OTC > Biotechs > Ampio Pharmaceuticals, Inc (AMPE)

Testing moves forward.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TJG Member Profile
Member Level 
Followed By 563
Posts 27,235
Boards Moderated 3
Alias Born 06/20/07
160x600 placeholder
Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled PR Newswire (US) - 1/14/2021 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:59:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 4:58:29 PM
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients PR Newswire (US) - 1/4/2021 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/29/2020 4:18:32 PM
Ampio Receives feedback from the FDA on Ampio's Proposed Modifications to the special protocol assessment for Ampion treatmen... PR Newswire (US) - 12/29/2020 9:15:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:41:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:39:02 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 6:37:51 PM
Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion PR Newswire (US) - 12/17/2020 9:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/15/2020 4:02:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2020 2:25:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2020 2:24:03 PM
Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug,... PR Newswire (US) - 12/10/2020 9:15:00 AM
Ampio Pharmaceuticals, Inc. to Host its Annual Meeting on December 12, 2020 PR Newswire (US) - 12/8/2020 9:15:00 AM
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress PR Newswire (US) - 12/2/2020 9:15:00 AM
Ampio Updates Regulatory and Clinical Trial Events PR Newswire (US) - 11/25/2020 9:15:00 AM
Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress PR Newswire (US) - 11/17/2020 9:15:00 AM
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress PR Newswire (US) - 11/10/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:02:00 PM
Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results PR Newswire (US) - 11/5/2020 3:45:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/3/2020 9:32:51 AM
Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th PR Newswire (US) - 11/2/2020 9:15:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 10/30/2020 11:21:24 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/30/2020 11:13:06 AM
TJG Member Level  Wednesday, 11/11/20 06:53:43 AM
Re: None
Post # of 1124 
Testing moves forward.

Ampios Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress
4:01 PM ET 11/10/20 | Dow Jones


ENGLEWOOD, Colo., Nov. 10, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the second group in the Phase I inhaled Ampion(TM) clinical study is being treated following clearance by the Safety Monitoring Committee (SMC) who found Ampion to be safe and well-tolerated after reviewing the results from the first treatment group.

Michael Macaluso, Ampio's, President and CEO, clarified specific features of this clinical trial:

-- "Ampion will be administered to patients by inhalation, allowing the drug

to directly target and attenuate inflammation in the lungs, using a

hand-held nebulizer for COVID-19 patients early in the disease and

non-invasive ventilation (face mask) and mechanical ventilation

(intubation) if their disease state is more severe.

-- This US study will enroll 40 patients, randomized 1 to 1, inhaled Ampion

versus Standard of Care (SOC), with each patient inhaling 8 mL doses of

Ampion four (4) times a day for five (5) days. Safety is the primary end

point and various measurements indicative of efficacy are secondary

endpoints.

-- Each of the first three patient groups receiving inhaled Ampion will be

assessed by the SMC for an additional three days after the 5 day

treatment period (as inhalation is a new method of administration of

Ampion cleared for clinical use by the FDA) and if no safety concerns

arise, open enrollment at the speed of recruitment will follow the

remainder of the 40 patients."

Mr. Macaluso further noted, "The FDA has now cleared two types of administration of Ampion for treatment of COVID-19 patients, inhalation and intravenous. In addition, a third method of administration, direct injection into the knee for patients suffering from severe osteoarthritis-of-the-knee, supports the Company's belief that Ampion is a platform drug, potentially useful for a number of inflammatory diseases throughout the body. We are currently investigating a similar inhalation study overseas that we are planning to run in close proximity with the US study. We will provide an update with more information as it develops."


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences